Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Part 1 of an ongoing 12-part COVID-19 series, Vikramjit Mukherjee, MD, provides a brief update on the latest incidence trends, the role of serology in disease assessment, and newly published data from the ACTT-1 trial comparing remdesivir vs placebo for severe COVID-19 treatment. After the update, Dr. Mukherjee answers critical clinician questions on COVID-19 transmission, diagnosis, and management.
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program: https://www.clinicaloptions.com/infectious-disease/programs/covid19-resources
Download slides reviewing the latest data and guidance on COVID-19 symptoms and clinical manifestations, from Clinical Care Options (CCO)
Downloadable slides from CCO on the rationale and evidence supporting timeliness in the administration of therapies that act directly against SARS-CoV-2
Download slides reviewing the latest data and guidance on COVID-19 treatments, including authorized and investigational agents, from Clinical Care Options (CCO)
Expert selections of important COVID-19 data from ECCMID 2022, including treatment, vaccination, and long COVID, from Clinical Care Options (CCO)